Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zaměřený na familiární hypercholesterolemii ve střední, jižní a východní Evropě: základní epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.
|Number of pages||6|
|Publication status||Published - 2017|
- Familial hypercholesterolemia
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine